|

CB-011 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Cyclophosphamide, Fludarabine

Pipeline

Phase 1: 1

Top Sponsors

  • Caribou Biosciences, Inc.1

Indications

  • Relapsed/ Refractory Multiple Myeloma1
  • Cancer1

Birmingham, Alabama1 trial

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

University of Alabama at Birmingham

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.